Key Points
- Director Robert Glassman sold 10,000 Pharvaris shares on May 15 at an average price of $29.82, reducing his ownership by about 48.8% to 10,500 shares.
- Pharvaris recently beat quarterly EPS estimates, reporting a loss of $0.70 per share versus the expected $0.82 loss, while analysts still forecast a full-year loss of -3.25 EPS.
- Analyst sentiment remains mostly positive, with 10 Buy ratings and an average target price of $49.18, though insider selling and mixed ratings from some firms may temper enthusiasm.
Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) Director Robert Glassman sold 10,000 shares of Pharvaris stock in a transaction on Friday, May 15th. The shares were sold at an average price of $29.82, for a total value of $298,200.00. Following the completion of the transaction, the director owned 10,500 shares in the company, valued at $313,110. This represents a 48.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Pharvaris Trading Up 0.5%
Shares of NASDAQ:PHVS opened at $28.95 on Wednesday. Pharvaris N.V. has a 12-month low of $15.46 and a 12-month high of $33.33. The business's fifty day simple moving average is $28.26 and its 200-day simple moving average is $26.68. The company has a market capitalization of $1.89 billion, a PE ratio of -9.10 and a beta of -2.34.
Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.82) by $0.12. Research analysts predict that Pharvaris N.V. will post -3.25 EPS for the current year.
More Pharvaris News
Here are the key news stories impacting Pharvaris this week:
- Positive Sentiment: HC Wainwright raised its earnings estimates for Pharvaris across multiple quarters and fiscal years, including higher forecasts for FY2026 through FY2030, and maintained a Buy rating with a $60 price target.
- Neutral Sentiment: Pharvaris recently reported a smaller-than-expected quarterly loss, with EPS of ($0.70) versus the consensus estimate of ($0.82), which may support sentiment but does not change the company’s near-term loss profile.
- Negative Sentiment: Insider selling by Director Robert Glassman and insider Wim Souverijns, both of whom sold 10,000 shares, may temper enthusiasm slightly because it can be viewed as reduced insider confidence. SEC filing for Robert Glassman sale SEC filing for Wim Souverijns sale
Analyst Upgrades and Downgrades
Several brokerages recently weighed in on PHVS. Wolfe Research began coverage on Pharvaris in a research note on Thursday, April 9th. They set an "outperform" rating and a $42.00 target price on the stock. UBS Group set a $74.00 target price on Pharvaris in a research note on Wednesday, May 13th. Weiss Ratings restated a "sell (d-)" rating on shares of Pharvaris in a research note on Tuesday, April 21st. Citigroup restated a "buy" rating on shares of Pharvaris in a research note on Wednesday, April 15th. Finally, Citizens Jmp dropped their target price on Pharvaris from $75.00 to $74.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 13th. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $49.18.
Get Our Latest Report on Pharvaris
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in PHVS. Wellington Management Group LLP purchased a new position in Pharvaris during the 3rd quarter worth $43,282,000. Paradigm Biocapital Advisors LP grew its stake in Pharvaris by 72.7% during the 3rd quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company's stock worth $45,796,000 after buying an additional 772,583 shares during the last quarter. Balyasny Asset Management L.P. purchased a new stake in Pharvaris during the 3rd quarter valued at about $15,613,000. Commodore Capital LP grew its stake in Pharvaris by 26.5% during the 3rd quarter. Commodore Capital LP now owns 2,418,476 shares of the company's stock valued at $60,341,000 after purchasing an additional 507,043 shares during the last quarter. Finally, General Atlantic L.P. grew its stake in Pharvaris by 6.6% during the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company's stock valued at $200,380,000 after purchasing an additional 500,000 shares during the last quarter.
About Pharvaris
(
Get Free Report)
Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.
The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
